Can we spot heart damage early during breast cancer therapy?
NCT ID NCT07588425
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 100 women with early-stage breast cancer who are receiving standard chemotherapy or anti-HER2 therapy. Researchers will use heart ultrasounds and blood tests to look for early signs of heart damage. The goal is to find better ways to detect cardiac side effects before they become serious.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors detect heart damage earlier during breast cancer treatment, potentially preventing long-term heart problems.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not lead to changes in care, and results might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gazi University Faculty of Medicine
Ankara, Ankara, 06560, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a PET scan reveal hidden heart harm from lung cancer treatment?
- Heart scans may unlock hidden risks in minority communities
- Chemotherapy's hidden heart toll: study probes lasting damage in breast cancer survivors
- Genetic panel aims to spot heart risk before cancer therapy begins
- Could thousands of women skip hormone therapy after breast cancer?
- Heart-Safe chemo? trial aims to shield patients from lifelong damage